Abstract: In exemplary embodiments, the disclosure provides a Colesevelam Colon Specific Drug Delivery System for use in treatment of, for example pruritus, a disorder related to elevated serum cholesterol concentration, or reducing elevated low-density lipoprotein cholesterol (LDL) concentration in a patient.

Abstract: Described are methods for treating or preventing IBS in subjects by administering molybdenum or a salt thereof to subjects having or prone of getting IBS. The molybdenum has been shown to treat or prevent IBS in subjects administered this agent when compared to reference subjects not administered molybdenum.

Abstract: The disclosure relates to the field of reducing malodor, which is due to bacterial conversion of molecules that are present in sweat. Indeed, the disclosure describes acids, which steer the microbiome by inhibiting the growth of specific malodor-producing bacteria and/or promoting the growth of bacteria known to be beneficial in relation to malodor. The acids of the disclosure can thus be used in deodorants, washing powders, clothing finishing agents or any method to reduce malodor. The disclosure thus relates to a topical composition or textile finisher for use as a prebiotic.

Abstract: Disclosed are an ethanol hardener and the use thereof. The ethanol hardener contains ethanol, a water-soluble iodine preparation and water, wherein the volume percent of the ethanol is 76-98%, and the mass-volume ratio of the iodine element in the water-soluble iodine preparation to the iodine containing composition is 23-139 g/L. The iodine containing composition can be autoradiographed when injected into blood vessels, and has a better embolization effect and stability.

Abstract: The present invention relates to improved formulations of propandiol mononitrate and derivatives thereof as well as to the production of such formulations.

Abstract: A discrete dispensed product comprising a first portion; and a second portion at least partially surrounding the first portion provides a premium and distinct appearance to consumers.

Abstract: Methods of making polytetrafluoroethylene (PTFE)/polymer composites are disclosed herein. The products can be used in the field of bio- and medical applications, such as for use in artificial blood vessels, vascular grafts, cardiovascular and soft tissue patches, facial implants, surgical sutures, and endovascular prosthesis, and for any products known in the aerospace, electronics, fabrics, filtration, industrial and sealant arts.

Abstract: The present invention relates to injectable compositions. More particularly, the present disclosure relates to injectable, thermogelling hydrogel formulations comprising at least one antibiotic for relieving and/or treating low back pain.

Abstract: The present invention is in the field of antiperspirant compositions, in particular, compositions comprising antiperspirant actives. Disclosed is an anhydrous antiperspirant composition comprising an inorganic polyionic cluster having structure of (I) or (II); where M is Ca or Mg; and wherein the composition is substantially free of abrasives, which means less than 3.0% by weight of the composition; wherein anhydrous means the water content of the composition is less than 3.0%.

Abstract: The present invention relates to compositions comprising molecular iodine and a vehicle comprising a semifluorinated alkane. The compositions of the invention may be used to treat or prevent diseases or conditions caused by, or associated with microorganisms.

Abstract: This invention provides for a gel texturizer base for cosmetic products. The bases are excipients that provide a gel-like texture to cosmetic products. The gel texturizer bases of this invention are from non-petroleum based products and comprise over 85% juice derived solvent with the balance being a combination of a texture enhancer and a gum texture modifier.

Abstract: The present invention relates to a pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea, or a pharmaceutically acceptable organic or inorganic acid salt thereof, a pharmaceutically acceptable organic or inorganic acid, a pharmaceutically acceptable beta- or gamma-cyclodextrin and water, that is a clear solution, with the proviso that the organic or inorganic acid (including a salt thereof) is not a sulphonic acid. Such a formulation is particularly suitable for intravenous or parenteral administration to a patient.

Abstract: The present invention provides an oral patch for localized treatment of mouth ulcers containing combination of tetracaine and triamcinolone as active drugs. The patch is a bilayer structure containing a drug layer with amorphous tetracaine hydrochloride and amorphous triamcinolone acetonide and a water-soluble backing layer without a drug. The oral patch with combination of drugs has improved efficacy over each individual drug. The drug layer comprises 3-20% by weight of amorphous tetracaine hydrochloride, or a pharmaceutical acceptable salt thereof, 0.1-2.0% by weight of amorphous triamcinolone acetonide or a pharmaceutical acceptable salt thereof, 20-95% by weight of a first film-forming material, 1-12% by weight of an adhesive, 1-20% by weight of one or more cooling agent, and optionally 1-12% by weight of a plasticizer. The backing layer comprises 70-95% by weight of one or more film-forming agents, 2-10% by weight of a plasticizer and optionally 1-8% by weight of a flavoring agent.

Abstract: Disclosed are personal care compositions, e.g., skin care compositions, comprising an acyl glutamate, e.g., sodium cocoyl glutamate, in an amount of from 1% to 10% by weight of the composition and at least one topically active compound, wherein the at least one topically active compound comprises a vitamin, as well as to methods of using these compositions.

Abstract: The application relates to personal care products (e.g., deodorants and/or antiperspirants) that can provide a sweat reduction effect without the use of aluminum salts. In one aspect, the compositions comprise a metal oxalate (i.e., potassium oxalate or potassium titanium oxalate). Methods of preparing the personal care composition and uses of the personal care composition are also disclosed.

Abstract: A makeup removal composition includes at least one silicone crosspolymer-based emulsifier, at least one polyglyceryl ester with HLB less than 10, at least one branched or linear liquid alkane with carbon chain length of C11 to C20, at least one polar emollient ester with carbon chain length of C12 to C24, water, or water and a water-based hydrating agent or solvent or combination thereof, and, optionally one or more additives.

Abstract: Provided is a cellulose composition, including a plurality of biocelluloses, wherein a diameter of the biocelluloses ranges from 20 to 30 nanometer, and a length of the biocelluloses ranges from 2000 to 3000 nanometer. The biocelluloses have good biocompatibility and can effectively enhance the efficiency of absorption and transmission of substances.

Abstract: Provided is a composition including: an acrylamide compound (A1) having a molecular weight of 150 or greater but 250 or less; and a multifunctional polymerizable compound (A2), wherein a content of the multifunctional polymerizable compound (A2) is 15% by mass or greater but 35% by mass or less.

Abstract: An 10-(2-hydroxyethyl)-9-(2-hydroxypyridin-3-yl)-3,4,6,7,9,10-hexahydroacridine-1,8(2H,5H)-dione compound, its synthesis, and its use as an antimicrobial agent.

Abstract: A method for removing keratotic plugs capable of sufficiently exhibiting an excellent keratotic plug-removing effect without a burden, such as pam and of irritation, on the skin. The method comprises applying a composition comprising (X) one or more selected from (X1) 2-amino-2-hydroxymethyl-1,3-propanediol, (X2) 2-amino-2-methyl-1-propanol, and (X3) 2-amino-2-methyl-1,3-propanediol and a nonionic surfactant to the skin.